EXIT 156 CAPITAL AND NIGHTWARE ANNOUNCE STRATEGIC INVESTMENT PARTNERSHIP

In this episode of Global Economic Press, Alex Brady discusses a significant development in the digital health sector involving NightWare, Inc., a Minneapolis-based company known for its innovative solutions for nightmare disorder in adults with post-traumatic stress disorder. NightWare has announced a strategic investment partnership with Exit 156 Capital, a Minneapolis-area investment firm. This collaboration aims to accelerate NightWare's growth and expand its reach in the healthcare market. The partnership will support NightWare's national Veterans Affairs Pathfinder Innovation Pilot, scale commercial employer-group insurance pilots, advance proprietary hardware development, and expand the company's patient management program toward a recurring revenue model. The NightWare-Exit 156 partnership reflects a shared conviction about the severity of the unmet clinical need and the strength of NightWare's commercial foundation. NightWare's system, which pairs an Apple Watch with a proprietary artificial intelligence application, is the only Food and Drug Administration-cleared prescription digital therapeutic for nightmare disorder in adults with post-traumatic stress disorder. The investment by Exit 156 Capital fits within the firm's focus on healthcare technology companies with defensible market positions and proven management teams. NightWare has generated over seven point five million dollars in cumulative revenue and is working to establish reimbursement across Veterans Affairs health system, commercial insurance, and direct-pay channels. For more information, visit NightWare's website.